Shots:

• The companies collaborated to accelerate drug target discovery using AI-based genome interpretation & genomic analysis techniques. The collaboration focuses to improve the efficiency of pharma pipelines using industry-leading ability to identify genetic variants for human disease
• The collaboration will use Illumina's AI-based interpretation tools, PrimateAI & SpliceAI with AstraZeneca's analysis framework for rare variant genomic discoveries & its AI tools. AstraZeneca's Centre for Genomics Research will use the combined framework to analyze large-scale multi-omics data sets in its digital biobank
• The combined framework has the potential to prioritize drug candidates with an increased likelihood of approval across human diseases

Ref: PRNewswire | Image: AstraZeneca